Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Sirna Therapeutics and Invitrogen and DNA Research Innovations

Sirna Therapeutics and Invitrogen and DNA Research Innovations

Nov 05, 2004
Premium

Sirna Reports 70-percent drop in Q3 Revenues

Sirna Therapeutics reported last week its financial results for the third quarter 2004, posting a sharp drop off in revenues amid a decline in expenses.

Sirna’s revenues for the third quarter were $84,000, compared with $283,000 in the year-ago period. The company attributed the 70 percent decline to the completion of ribozyme-related manufacturing programs as its new aptamer manufacturing arrangement with Archemix gets underway.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Vaccine Authorization

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

Healthcare Workers, Nursing Home Residents First

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

Hackers Target Vaccine Makers

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

Cell Studies on Months-Long SARS-CoV-2 Shedding, Spike Mutation, Ebola Infection Dynamics

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.

Dec
03
Featured Webinar

Leveraging Multi-Omic Approaches to Understand Disease Stem Cells in Myeloid Malignancies

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Featured Webinar

Accelerating Forward Engineering and Genome Discovery with CRISPR: E. Coli Case Studies

Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology. 

What's Popular?

In Gene Silencing/Gene Editing

  1. Horizon Discovery Licenses Gene-Edited Cell Line to Sanyou Biopharmaceuticals

  2. ERS Genomics Licenses CRISPR Patents to German Startup Vivlion

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.